To provide basic information about occurrence and outcome of essential thrombocythemia
(ET) and agnogenic myeloid metaplasia (AMM), we used the Rochester Epidemiology …

Myelofibrotic transformation is a known complication of essential thrombocythaemia (ET),
but information on its incidence, presenting features and evolution is scarce. In a series of …

OBJECTIVE To describe the long-term natural history of essential thrombocythemia (ET) in
terms of life expectancy, risk of disease transformation into a more aggressive myeloid …

Unlike the case with thrombosis, prognostic models for survival and leukemic transformation
(LT) in essential thrombocythemia (ET) are not available. Among 605 patients with ET seen …

Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology
in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis …

A total of 187 consecutive patients with essential thrombocythemia (ET) were diagnosed and
followed by our Hematology Department in the period October 1980–November 1994. The …

Background Essential thrombocythemia (ET) is a clonal myeloproliferative disease
associated with thrombohemorrhagic complications and myeloid transformation to diseases …

A set of clinical and pathological criteria for the diagnosis and staging of Philadelphia
chromosome-negative myeloproliferative disorders (Ph 1--MPDs) is presented by including …

We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between
1967 and 2023: median age 58 years (18–90), females 63%, JAK2/CALR/MPL-mutated …

Background Essential thrombocythemia is a chronic myeloproliferative disorder; patients
with this disorder have a propensity to develop thrombosis, myelofibrosis, and leukemia …